Indian drugmaker Lupin has landed an exclusive deal to bring a new fortnightly GLP‑1 injection, Bofanglutide, to the Indian market.
Deal Overview
Lupin signed an exclusive licensing, supply and distribution agreement with China’s Gan & Lee Pharmaceuticals. Under the pact, Lupin will be the only company able to sell and distribute Bofanglutide in India.
About Bofanglutide
- Designed for adults with type‑2 diabetes and for weight management in overweight or obese patients.
- Administered once every two weeks, cutting injection frequency by half compared with weekly GLP‑1 drugs.
- Clinical data suggest weight‑loss results that match or exceed existing weekly GLP‑1 treatments.
- Safety profile is similar to other drugs in the GLP‑1 class.
Why It Matters for India
India faces a growing metabolic‑health crisis:
- ≈174 million adults are overweight.
- ≈50 million adults are obese.
- ≈90 million adults live with diabetes.
Introducing a convenient, effective therapy could help address this public‑health challenge.
Company Comments
Nilesh Gupta, Managing Director, Lupin said the partnership reflects Lupin’s focus on chronic metabolic diseases and its strategy to expand the GLP‑1 drug portfolio.
Rajeev Sibal, President – India Region Formulations, Lupin highlighted that the twice‑monthly dosing cuts injections by 50% while delivering efficacy that matches or beats weekly options.
Kai Du, EVP & Chief Commercial Officer, Gan & Lee noted the deal follows a recent exclusive agreement for Latin America and fits the company’s global expansion plan.
Dhaval Soneji, Key Accounts Director, Gan & Lee added that the collaboration showcases Chinese biotech innovation and aims to improve treatment options worldwide.
Market Impact
Lupin’s shares have struggled this year, down about 12% year‑to‑date, but the new agreement could provide a fresh catalyst for growth.
Remember, this is perspective, not prediction. Do your own research before making any investment decisions.